Quantcast

Garden State Times

Thursday, November 21, 2024

New Jersey: Biologics companies were the second least FDA inspected companies in New Jersey in Q1 2023

Webp ishuwpt6uyanzpnvvfpnzrwi0yoq

Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website

Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website

In the first quarter of 2023, four Biologics companies received four FDA inspections in New Jersey, according to the U.S. Food and Drug Administration (FDA).

This was the second lowest number of inspections per type of company made by the FDA in New Jersey, equalling 5.2% of all inspections in the first quarter of 2023.

Of all the New Jersey companies involved in the Biologics sector, AtlantiCare Regional Medical Center IRB received the most citations from the FDA in the first quarter of 2023.

The FDA routinely inspects facilities across the nation to determine if the workplaces and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly for businesses to consistently make smarter business decisions for the future.

The FDA is a government agency primarily responsible for monitoring the manufacturing and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.

Top 10 FDA Inspections by Number of Actions Indicated in New Jersey During Q1 2023
Project AreaNo Action IndicatedVoluntary Action IndicatedOfficial Action Indicated
Bioresearch Monitoring33--
Blood and Blood Products12--
Compliance: Devices26--
Drug Quality Assurance422
Food Composition, Standards, Labeling and Econ61--
Foodborne Biological Hazards33161
Human Cellular, Tissue, and Gene Therapies11--
Monitoring of Marketed Animal Drugs, Feed, and Devices1----
Postmarket Assurance: Devices22--
Vaccines and Allergenic Products3----

MORE NEWS